Regular ArticleShedding of CD163, a Novel Regulatory Mechanism for a Member of the Scavenger Receptor Cysteine-Rich Family☆
References (33)
- et al.
Trends Biochem. Sci.
(1994) - et al.
J. Biol. Chem.
(1997) - et al.
J. Biol. Chem.
(1995) - et al.
J. Biol. Chem.
(1997) - et al.
Immunol. Today
(1993) Immunol. Today
(1995)- et al.
Eur. J. Immunol.
(1993) Curr. Opin. Lipidol.
(1997)- et al.
Eur. J. Immunol.
(1997) - et al.
Nature
(1991)
Int. Arch. Allergy Appl. Immunol.
(1990)
Exp. Cell Biol.
(1987)
J. Peridontal Res.
(1989)
Inflam. Res.
(1995)
Pharm. Res.
(1998)
Immunol. Methods
(1982)
Cited by (140)
Nanobodies against porcine CD163 as PRRSV broad inhibitor
2023, International Journal of Biological MacromoleculesEvaluation of sCD163 and sTWEAK in patients with stable peripheral arterial disease and association with disease severity as well as long-term mortality
2021, AtherosclerosisCitation Excerpt :CD163 is seen as a marker of differentiation in the macrophage lineage and its best studied role is binding of hemoglobin-haptoglobin complexes [12–14]. Similar to sTWEAK, CD163 can also be shed from cells and change into a soluble form [15]. The function of sCD163 remains mostly unclear.
Attributes of alternatively activated (M2) macrophages
2019, Life Sciences
- ☆
Abbreviations used: SRCR, scavenger receptor cysteine-rich; PMA, phorbol 12-myristate 13-acetate; PKC, protein kinase C; FP, Fluticasone-17-propionate; BIM, bisindolylmaleimide
- 1
To whom correspondence should be addressed at Institut für Experimentelle Dermatologie, Von-Esmarch-Str. 56, 48149 Münster, Germany. Fax: +49 251 835 6549. E-mail:[email protected].
Copyright © 1999 Academic Press. All rights reserved.